Rare Disease Trial, By Invitation NCT05236595 Sponsor: Mayo Clinic Condition: Rare Disease
Back to Rare Disease

Rare Disease Trial, By Invitation

NCT05236595
By Invitation Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • The person must have a Mayo Clinic, another health system ID, or some other unique identifying number.
  • The person must be able to give their informed consent to participate.
  • The person must have a confirmed or strongly suspected genetic disorder, identified by a doctor or genetic counsellor, with a specific genetic change found through laboratory testing.
  • The genetic change must be one that researchers believe could potentially be targeted by a type of drug called an antisense oligonucleotide (a treatment designed to interact with genetic material in specific ways to correct how genes work).
  • The person must be able to travel to a Mayo Clinic location for ongoing treatment if a therapy is developed.
  • Based on current medical understanding, treatment at the person's current stage of illness would likely be beneficial.
  • Alternatively, a biological family member of someone already enrolled in the trial may also be eligible, provided they can give informed consent — or have a legally authorised representative who can do so on their behalf.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People whose personal circumstances would make it difficult to follow the study's requirements.
  • People who are currently held in an institution such as a federal medical prison.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 13 August 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
By Invitation
Phase
Not Applicable
Sponsor
Registry
ClinicalTrials.gov
Start date
24 November 2021
Est. completion
1 November 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Enrollment of study participants; Collection of biospecimens; Partnered research with external entities; Future IND applications; Determine natural history and clinical baseline; Determine individualized therapeutic efficacy; Publish findings

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 13 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov